Have Insiders Sold Applied Therapeutics Shares Recently?
Have Insiders Sold Applied Therapeutics Shares Recently?
We'd be surprised if Applied Therapeutics, Inc. (NASDAQ:APLT) shareholders haven't noticed that the Chair of the Board of Directors, Shoshana Shendelman, recently sold US$267k worth of stock at US$4.32 per share. On the bright side, that sale was only 1.2% of their holding, so we doubt it's very meaningful, on its own.
如果Applied Therapeutics, Inc. (NASDAQ: APLT)的股东没有注意到董事会主席Shoshana Shendelman最近以4.32美元每股的价格出售了267,000美元的股票,那么我们会感到惊讶。好的一面是,那笔交易只占他们持股的1.2%,所以我们怀疑它本身并不重要。
The Last 12 Months Of Insider Transactions At Applied Therapeutics
应用疗法内部交易的最后12个月
In fact, the recent sale by Chair of the Board of Directors Shoshana Shendelman was not their only sale of Applied Therapeutics shares this year. They previously made an even bigger sale of -US$1.7m worth of shares at a price of US$5.39 per share. So what is clear is that an insider saw fit to sell at around the current price of US$5.27. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.
事实上,董事会主席Shoshana Shendelman最近的股票交易不是他们今年Applied Therapeutics股票唯一的交易。 他们以每股5.39美元的价格出售了价值1.7美元的更多的股票。因此,很明显,内部人士认为以目前的5.27美元的价格出售是恰当的。虽然内部卖出是一件负面的事情,但对我们来说,如果股票以更低的价格卖出,它会更加负面。我们注意到这次交易发生在当前价格附近,因此这不是一个主要问题,但这并不是一个好的迹象。
Over the last year we saw more insider selling of Applied Therapeutics shares, than buying. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
在过去的一年中,我们看到了更多Applied Therapeutics股票的内部卖出,而不是买入。您可以在下面的图表中看到过去一年内公司和个人的内部交易。如果您想知道谁卖了,以及以多少价格和何时出售,只需单击下面的图表即可!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240613/0-db8e085dbee777bde980a9471ee26f1f-0-2f2d17b87d15c9bf10ef01b29ba70885.png/big)
I will like Applied Therapeutics better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
如果我看到一些内部人员的大宗交易,我会更喜欢购买Applied Therapeutics。同时等待之际,请查看此免费的具有相当、最近有内部买入的小盘低估值股票清单。
Insider Ownership
内部人员持股情况
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 6.1% of Applied Therapeutics shares, worth about US$37m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
我喜欢看内部人持有公司的股票数量,以帮助我了解他们与内部人员的利益是否一致。如果内部人持有公司的股份比较多,那么我认为这是一个好的迹象。股东持有Applied Therapeutics股票的比例为6.1%,价值约为37,000,000美元。这种内部股权所有权的水平不错,但并不特别突出。它确实表明有合理的一致性。
What Might The Insider Transactions At Applied Therapeutics Tell Us?
Applied Therapeutics的内部交易可能告诉我们什么?
Insiders haven't bought Applied Therapeutics stock in the last three months, but there was some selling. Zooming out, the longer term picture doesn't give us much comfort. While insiders do own shares, they don't own a heap, and they have been selling. So we'd only buy after careful consideration. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Be aware that Applied Therapeutics is showing 4 warning signs in our investment analysis, and 2 of those are a bit concerning...
内部人士在过去三个月中没有购买Applied Therapeutics的股票,但有一些卖出。展望更长期的情况,它并没有给我们带来太多的安慰。虽然内部人士拥有股份,但他们拥有的不多,并且一直在卖出。因此,在仔细考虑后,我们才会购买。虽然我们喜欢了解内部人员持股和交易情况,但在做出任何投资决策之前,我们一定要考虑股票面临的风险。请注意,Applied Therapeutics在我们的投资分析中显示有4个警告信号,其中有2个有点令人担忧......
Of course Applied Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然,Applied Therapeutics可能不是最好的买入股票。因此,您可能希望查看这个免费的高质量公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。